ALNYLAM PHARMACEUTICALS, INC revenue breakdown overview

ALNYLAM PHARMACEUTICALS, INC revenue for the last year amounted to 46.87 B MXN, the most of which — 46.87 B MXN — came from its highest performing source at the moment, Ribonucleic Acid Interference Therapeutics, the year earlier bringing 31.05 B MXN. The greatest contribution to the revenue figure was made by United States — last year it brought ALNYLAM PHARMACEUTICALS, INC 32.02 B MXN, and the year before that — 21.67 B MXN.